Michael Wiederhorn
Stock Analyst at Oppenheimer
(4.75)
# 648
Out of 5,023 analysts
1099
Total ratings
58%
Success rate
10.5%
Average return
Main Sectors:
Stocks Rated by Michael Wiederhorn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CI The Cigna Group | Reiterated: Buy | $365 | $270.53 | +34.92% | 75 | Oct 1, 2026 | |
| ENSG The Ensign Group | Reiterated: Buy | $210 | $171.78 | +22.25% | 89 | Sep 22, 2026 | |
| ASTH Astrana Health | Initiated Coverage: Buy | $53 | $35.88 | +47.71% | 1 | Sep 15, 2026 | |
| HCSG Healthcare Services Group | Initiated Coverage: Buy | $28 | $20.87 | +34.16% | 1 | Aug 19, 2026 | |
| PACS PACS Group | Reiterated: Buy | $48 → $57 | $42.85 | +33.02% | 6 | Aug 10, 2026 | |
| EVH Evolent Health | Rated: Buy | $6 | $3.46 | +73.41% | 13 | Aug 7, 2026 | |
| GRDN Guardian Pharmacy Services | Reiterated: Buy | $43 → $49 | $42.38 | +15.62% | 8 | Aug 7, 2026 | |
| TDOC Teladoc Health | Rated: Buy | $7 | $5.52 | +26.81% | 31 | Aug 4, 2026 | |
| CHE Chemed | Rated: Buy | $500 → $590 | $507.50 | +16.26% | 118 | Jul 31, 2026 | |
| HUM Humana | Rated: Buy | $260 → $405 | $388.36 | +4.28% | 80 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $520 → $485 | $426.69 | +13.67% | 96 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $2.72 | +47.06% | 121 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $405 → $500 | $371.90 | +34.44% | 88 | Jul 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $39.24 | +1.94% | 18 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $155 | $111.27 | +39.30% | 113 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $45 → $58 | $62.99 | -7.92% | 163 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $86.46 | n/a | 17 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.0001 | n/a | 6 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $39.82 | n/a | 1 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $386.43 | n/a | 48 | Jun 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 | $0.000001 | n/a | 6 | Aug 19, 2014 |
The Cigna Group
Oct 1, 2026
Reiterated: Buy
Price Target: $365
Current: $270.53
Upside: +34.92%
The Ensign Group
Sep 22, 2026
Reiterated: Buy
Price Target: $210
Current: $171.78
Upside: +22.25%
Astrana Health
Sep 15, 2026
Initiated Coverage: Buy
Price Target: $53
Current: $35.88
Upside: +47.71%
Healthcare Services Group
Aug 19, 2026
Initiated Coverage: Buy
Price Target: $28
Current: $20.87
Upside: +34.16%
PACS Group
Aug 10, 2026
Reiterated: Buy
Price Target: $48 → $57
Current: $42.85
Upside: +33.02%
Evolent Health
Aug 7, 2026
Rated: Buy
Price Target: $6
Current: $3.46
Upside: +73.41%
Guardian Pharmacy Services
Aug 7, 2026
Reiterated: Buy
Price Target: $43 → $49
Current: $42.38
Upside: +15.62%
Teladoc Health
Aug 4, 2026
Rated: Buy
Price Target: $7
Current: $5.52
Upside: +26.81%
Chemed
Jul 31, 2026
Rated: Buy
Price Target: $500 → $590
Current: $507.50
Upside: +16.26%
Humana
Jul 30, 2026
Rated: Buy
Price Target: $260 → $405
Current: $388.36
Upside: +4.28%
Jul 27, 2026
Reiterated: Buy
Price Target: $520 → $485
Current: $426.69
Upside: +13.67%
Jul 24, 2026
Reiterated: Buy
Price Target: $4
Current: $2.72
Upside: +47.06%
Jul 17, 2026
Rated: Buy
Price Target: $405 → $500
Current: $371.90
Upside: +34.44%
May 8, 2026
Reiterated: Buy
Price Target: $40
Current: $39.24
Upside: +1.94%
May 6, 2026
Rated: Buy
Price Target: $155
Current: $111.27
Upside: +39.30%
Apr 29, 2026
Rated: Buy
Price Target: $45 → $58
Current: $62.99
Upside: -7.92%
Aug 9, 2024
Reiterated: Hold
Price Target: n/a
Current: $86.46
Upside: n/a
Mar 2, 2023
Reiterated: Buy
Price Target: $3
Current: $0.0001
Upside: n/a
Feb 9, 2018
Reiterated: Buy
Price Target: $35
Current: $39.82
Upside: n/a
Jun 7, 2017
Rated: Hold
Price Target: n/a
Current: $386.43
Upside: n/a
Aug 19, 2014
Rated: Buy
Price Target: $7
Current: $0.000001
Upside: n/a